Prosthesis Mismatch in TAVR: It’s Real Impact

Prosthesis-patient mismatch (PPM) was initially proposed by Rahimtoola and reintroduced by Pirabot.

La prudencia es buena consejera para decidir una transfusión en el TAVI

PPM is the indexed effective orifice area in relation to body surface area, cutoff value being 0.85 cm2/m2, and <0.70 cm2/m2for obese patients. PPM is considered moderate if indexed effective orifice area is 0.65-0.85 cm2/m2 and severe when <0.65 cm2/m2 

Research studies on surgical prosthesis have associated PPM with higher mortality at short, mid and long term. 

There are few studies on post TAVR PPM. Unlike surgical prosthesis, its impact remains to be shown. 

The current study is a meta-analysis of 23 studies with a total 81969 patients. 19612 presented some degree of PPM (23.9%).

Mortality was higher in patients presenting moderate/severe PPM (HR: 1.09 [95% CI: 1.04-1.14]; P < 0.001).

Within the first 30 months, mortality was higher in patients with moderate to severe PPM (HR: 1.1 [95% CI: 1.05-1.16]; P < 0.001). After 30 days, even though mortality was slightly higher, it did not reach statistical significance (HR 0.83 [95% CI: 0.68-1.01]; P = 0.064).

Read also: AQCA Study: Pre-PCI Virtual QFR for Planning PCI vs. Conventional Angiography.

Additionally, PPM moderate and severe were looked at separately, resulting in higher mortality the with more severe PPM, vs. patients with no PPM (HR: 1.25 [95% CI: 1.16-1.36]; P < 0.001). However, this was not the case when looking at moderate PPM (HR: 1.03 [95% CI: 0.96-1.10]; P = 0.398). 

Conclusion

Severe PPM was associated to higher mortality at TAVR followup (unlike moderate PPM). These outcomes call for strategies to prevent severe PPM. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Impact of Prosthesis-Patient Mismatch After Transcatheter Aortic Valve Replacement Meta-Analysis of Kaplan-Meier–Derived Individual Patient Data.

Reference: Michel Pompeu Sá, et al. J Am Coll Cardiol Img 2023;16:298–310.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...